Declining liver graft quality threatens the future of liver transplantation in the United States

Liver Transplantation

Volumn 21, Issue 8, 2015, Pages 1040-1050

  Orman, Eric S ^a,c   Mayorga, Maria E ^d   Wheeler, Stephanie B ^b   Townsley, Rachel M ^d   Toro Diaz, Hector H ^e   Hayashi, Paul H ^a   Sidney Barritt, A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c INDIANA UNIVERSITY   (United States)

^d North Carolina State University   (United States)

^e Clemson University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; FEMALE; HEALTH CARE POLICY; HUMAN; LIVER GRAFT; LIVER PERFUSION; LIVER TRANSPLANTATION; LIVER WEIGHT; MALE; ORGAN DONOR; PRIORITY JOURNAL; ADVERSE EFFECTS; COMPUTER SIMULATION; DONOR; DONOR SELECTION; FACTUAL DATABASE; FORECASTING; GRAFT SURVIVAL; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH SERVICE; MIDDLE AGED; NEEDS ASSESSMENT; POSTOPERATIVE COMPLICATIONS; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SUPPLY AND DISTRIBUTION; THEORETICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; TRENDS; UNITED STATES;

ADULT; COMPUTER SIMULATION; DATABASES, FACTUAL; DONOR SELECTION; FEMALE; FORECASTING; GRAFT SURVIVAL; HEALTH CARE RATIONING; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, THEORETICAL; NEEDS ASSESSMENT; POSTOPERATIVE COMPLICATIONS; PROCESS ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84937960640     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24160     Document Type: Article

References (49)

1. Health Resources and Services Administration. OPTN/SRTR 2011 Annual Data Report. Rockville, MD: US Department of Health and Human Services; 2012.
2. D'Amico G, Garcia-Tsao G, Pagliaro L,. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231.
3. Merion RM, Pelletier SJ, Goodrich N, Englesbe MJ, Delmonico FL,. Donation after cardiac death as a strategy to increase deceased donor liver availability. Ann Surg 2006; 244: 555-562.
4. McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA,. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 2007; 246: 940-946.
5. Gabrielli M, Moisan F, Vidal M, Duarte I, Jiménez M, Izquierdo G, et al., Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study. Ann Hepatol 2012; 11: 891-898.
6. Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, et al., Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003; 9: 500-505.
7. Leithead JA, Tariciotti L, Gunson B, Holt A, Isaac J, Mirza DF, et al., Donation after cardiac death liver transplant recipients have an increased frequency of acute kidney injury. Am J Transplant 2012; 12: 965-975.
8. Mathur AK, Heimbach J, Steffick DE, Sonnenday CJ, Goodrich NP, Merion RM,. Donation after cardiac death liver transplantation: predictors of outcome. Am J Transplant 2010; 10: 2512-2519.
9. Jay C, Ladner D, Wang E, Lyuksemburg V, Kang R, Chang Y, et al., A comprehensive risk assessment of mortality following donation after cardiac death liver transplant-an analysis of the national registry. J Hepatol 2011; 55: 808-813.
10. Orman ES, Barritt AS 4th, Wheeler SB, Hayashi PH,. Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death. Liver Transpl 2013; 19: 59-68.
11. From the Centers for Disease Control and Prevention. Public health and aging: trends in aging - United States and worldwide. JAMA 2003; 289: 1371-1373.
12. Flegal KM, Carroll MD, Kit BK, Ogden CL,. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307: 491-497.
13. Shafer TJ, Wagner D, Chessare J, Zampiello FA, McBride V, Perdue J,. Organ donation breakthrough collaborative: increasing organ donation through system redesign. Crit Care Nurse 2006; 26: 33-42, 44-48.
14. Karnon J,. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ 2003; 12: 837-848.
15. Alagoz O, Bryce CL, Shechter S, Schaefer A, Chang CC, Angus DC, Roberts MS,. Incorporating biological natural history in simulation models: empirical estimates of the progression of end-stage liver disease. Med Decis Making 2005; 25: 620-632.
16. Shechter SM, Bryce CL, Alagoz O, Kreke JE, Stahl JE, Schaefer AJ, et al., A clinically based discrete-event simulation of end-stage liver disease and the organ allocation process. Med Decis Making 2005; 25: 199-209.
17. Berg B, Denton B, Nelson H, Balasubramanian H, Rahman A, Bailey A, Lindor K,. A discrete event simulation model to evaluate operational performance of a colonoscopy suite. Med Decis Making 2010; 30: 380-387.
18. Elgart JF, Caporale JE, Gonzalez L, Aiello E, Waschbusch M, Gagliardino JJ,. Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. Health Econ Rev 2013; 3: 11.
19. Tran-Duy A, Boonen A, van de Laar MA, Franke AC, Severens JL,. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. Ann Rheum Dis 2011; 70: 2111-2118.
20. Toro-Diaz H, Mayorga ME, Barritt AS, Orman ES, Wheeler SB,. Predicting liver transplant capacity using discrete event simulation. Med Decis Making 2014; pii: 0272989X14559055.
21. Clark JM, Brancati FL, Diehl AM,. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967.
22. Hayashi PH, Axelrod DA, Galanko J, Salvalaggio PR, Schnitzler M,. Regional differences in deceased donor liver transplantation and their implications for organ utilization and allocation. Clin Transplant 2011; 25: 156-163.
23. Rogers EM,. Diffusion of Innovations. 4th ed. New York: Free Press; 1995.
24. Sampson BG, O'Callaghan GP, Russ GR,. Is donation after cardiac death reducing the brain-dead donor pool in Australia? Crit Care Resusc 2013; 15: 21-27.
25. Bendorf A, Kelly PJ, Kerridge IH, McCaughan GW, Myerson B, Stewart C, Pussell BA,. An international comparison of the effect of policy shifts to organ donation following cardiocirculatory death (DCD) on donation rates after brain death (DBD) and transplantation rates. PLoS One 2013; 8: e62010.
26. Abadie A, Gay S,. The impact of presumed consent legislation on cadaveric organ donation: a cross-country study. J Health Econ 2006; 25: 599-620.
27. Gimbel RW, Strosberg MA, Lehrman SE, Gefenas E, Taft F,. Presumed consent and other predictors of cadaveric organ donation in Europe. Prog Transplant 2003; 13: 17-23.
28. Healy K,. The Political Economy of Presumed Consent. Los Angeles, CA: University of California; 2005. https://escholarship.org/uc/item/33x4463s.
29. Neto GB, Katarina Campelo A, Nunes da Silva E,. The Impact of Presumed Consent Law on Organ Donation: An Empirical Analysis from Quantile Regression for Longitudinal Data. Berkeley, CA: University of California; 2007. https://escholarship.org/uc/item/46670901.
30. Rithalia A, McDaid C, Suekarran S, Myers L, Sowden A,. Impact of presumed consent for organ donation on donation rates: a systematic review. BMJ 2009; 338: a3162.
31. Singh SK, Kim SJ,. Does expanded criteria donor status modify the outcomes of kidney transplantation from donors after cardiac death? Am J Transplant 2013; 13: 329-336.
32. Nagaraja P, Roberts GW, Stephens M, Horvath S, Fialova J, Chavez R, et al., Influence of delayed graft function and acute rejection on outcomes after kidney transplantation from donors after cardiac death. Transplantation 2012; 94: 1218-1223.
33. de Vries EE, Hoogland PE, Wind J, Snoeijs MG, van Heurn EL,. Transplantation of kidneys from paediatric DCD donors: a comparison with DBD donors. Nephrol Dial Transplant 2013; 28: 220-226.
34. Cohen B, Smits JM, Haase B, Persijn G, Vanrenterghem Y, Frei U,. Expanding the donor pool to increase renal transplantation. Nephrol Dial Transplant 2005; 20: 34-41.
35. Sharma A, Ashworth A, Behnke M, Cotterell A, Posner M, Fisher RA,. Donor selection for adult-to-adult living donor liver transplantation: well begun is half done. Transplantation 2013; 95: 501-506.
36. Trotter JF, Wisniewski KA, Terrault NA, Everhart JE, Kinkhabwala M, Weinrieb RM, et al.,; for A2ALL Study Group. Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology 2007; 46: 1476-1484.
37. Knaak JM, Spetzler VN, Goldaracena N, Boehnert MU, Bazerbachi F, Louis KS, et al., Subnormothermic ex vivo liver perfusion reduces endothelial cell and bile duct injury after donation after cardiac death pig liver transplantation. Liver Transpl 2014; 20: 1296-1305.
38. Knaak JM, Spetzler VN, Goldaracena N, Louis KS, Selzner N, Selzner M,. Technique of subnormothermic ex vivo liver perfusion for the storage, assessment, and repair of marginal liver grafts. J Vis Exp 2014; 90: e51419.
39. Whitson BA, Black SM,. Organ assessment and repair centers: The future of transplantation is near. World J Transplant 2014; 4: 40-42.
40. Guarrera JV, Henry SD, Samstein B, Reznik E, Musat C, Lukose TI, et al., Hypothermic machine preservation facilitates successful transplantation of "orphan" extended criteria donor livers. Am J Transplant 2015; 15: 161-169.
41. Yoo SS,. 3D-printed biological organs: medical potential and patenting opportunity. Expert Opin Ther Pat 2015; 25: 507-511.
42. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW,. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
43. Charlton M,. Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain? Hepatology 2008; 47: 1431-1433.
44. Viviane A, Alan BN,. Estimates of costs of hospital stay for variceal and nonvariceal upper gastrointestinal bleeding in the United States. Value Health 2008; 11: 1-3.
45. Stepanova M, Mishra A, Venkatesan C, Younossi ZM,. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 2012; 10: 1034-1041.
46. Mishra A, Otgonsuren M, Venkatesan C, Afendy M, Erario M, Younossi ZM,. The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample. Liver Int 2013; 33: 1281-1286.
47. Salvalaggio PR, Dzebisashvili N, MacLeod KE, Lentine KL, Gheorghian A, Schnitzler MA, et al., The interaction among donor characteristics, severity of liver disease, and the cost of liver transplantation. Liver Transpl 2011; 17: 233-242.
48. Axelrod DA, Schnitzler M, Salvalaggio PR, Swindle J, Abecassis MM,. The economic impact of the utilization of liver allografts with high donor risk index. Am J Transplant 2007; 7: 990-997.
49. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA,. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253.